NCT02622932View on ClinicalTrials.gov

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 2, 2015

Primary Completion Date

December 30, 2016

Study Completion Date

August 31, 2017

Conditions
Advanced Solid Tumors
Interventions
DRUG

Anlotinib and 14C-labeled Anlotinib

oral

Trial Locations (1)

210029

Jiangsu Province Hospital, Nanjing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY